Bendamustine in combination with rituximab can continue to be made available within NHS Wales for the treatment of previously untreated and relapsed mantle cell lymphoma in patients currently deemed unsuitable for anthracycline-based therapy or other health technology appraisal-approved regimens.

The risks and benefits of the off-label use of bendamustine plus rituximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.